Efficacy and Safety of 2L therapies for RS+ patients

Opinion
Video

  • Please discuss the efficacy and safety findings from studies supporting currently available 2L therapies and how they inform your treatment choices for patients who are RS positive:
  • IMerge (Platzbecker et al. Lancet 2024) (Santini et al. EHA 2024, Abstr. S184)
  • MEDALIST (Fenaux et al. NEJM 2020) (Santini et al. ASH 2023, Abstr. 915)
  • Please describe the similarities/differences between the two trials regarding the data related to defining transfusion independence.
  • Compare/contrast the data from IMerge and MEDALIST for patients based on whether they received (a) 2 to <4 units, (b) 4 to <6, or (c) ≥6 units every 8 weeks
Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Jamie L. Koprivnikar, MD, an expert on MDS
Related Content
Phase 3 Trial of Bomedemstat in Essential Thrombocythemia Begins Enrollment

Phase 3 Trial of Bomedemstat in Essential Thrombocythemia Begins Enrollment

Sabrina Serani
September 12th 2024
Article

The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential thrombocythemia.

Read More

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Nichole Tucker
June 30th 2023
Podcast

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Listen

Enrollment Begins in Phase 3 SOHO-02 Trial of BAY 2927088 in NSCLC

Enrollment Begins in Phase 3 SOHO-02 Trial of BAY 2927088 in NSCLC

Jordyn Sava
August 29th 2024
Article

The phase 3 SOHO-02 trial has enrolled its first patient with advanced non–small cell lung cancer harboring activating HER2 mutations.

Read More

Fezolinetant Trial for Hot Flashes in Patients With HR+ Breast Cancer Starts Enrollment

Fezolinetant Trial for Hot Flashes in Patients With HR+ Breast Cancer Starts Enrollment

Sabrina Serani
August 29th 2024
Article

The phase 3 study will investigate fezolinetant for vasomotor symptoms in patients receiving adjuvant endocrine therapy.

Read More

First Patient Enrolled in ON-SITE Study of AI-Based Image Analysis for Lung Cancer Detection

First Patient Enrolled in ON-SITE Study of AI-Based Image Analysis for Lung Cancer Detection

Jordyn Sava
August 17th 2024
Article

The ON-SITE study has enrolled its first patient to evaluate an AI-based image analysis module for lung cancer.

Read More

AFFINITY Study Completes Enrollment for Novel Aliya PEF System in Advanced Lung Cancer

AFFINITY Study Completes Enrollment for Novel Aliya PEF System in Advanced Lung Cancer

Jordyn Sava
August 9th 2024
Article

The AFFINITY study has finished enrolling participants to evaluate the Aliya pulsed electric field system in patients with stage IV non–small cell lung cancer or lung metastases who are not candidates for surgery.

Read More